EPISODE · Feb 19, 2026 · 1 MIN
FDA Approves Pembrolizumab for PD-L1-Positive Ovarian Cancer
from TheBrief.Health · host TheBrief.Health
FDA approves pembrolizumab combinations for PD-L1–positive, platinum-resistant ovarian cancer, improving progression-free and overall survival, offering new hope for patients with limited treatment options.
What this episode covers
FDA approves pembrolizumab combinations for PD-L1–positive, platinum-resistant ovarian cancer, improving progression-free and overall survival, offering new hope for patients with limited treatment options.
NOW PLAYING
FDA Approves Pembrolizumab for PD-L1-Positive Ovarian Cancer
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m